Literature DB >> 9034594

Immunotherapy I: Cyclosine gene transfer strategies.

M P Colombo1, G Forni.   

Abstract

The cytokine approach to gene therapy of cancer stems from early studies of direct, repeated injection of recombinant cytokines at the tumor site, and extension of the bystander effect that enables a few cytokine gene transduced cells in a tumor to bring about its total destruction. This effect can be extended through the immune system, since cytokine-activated regression of a small mass of tumor cells can afford systemic protection. Transduced cells used as a vaccine provide a local concentration of both cytokine and tumor antigens. Cytokines sustain antigen uptake and presentation by increasing the immunogenic potential of the environment through the recruitment of antigen presenting cells and leukocytes, and activation of a cascade of events which amplify and tone up the efficacy of a vaccine. The promises and difficulties of this approach are discussed by considering what is still missing from experimental studies and what can best be done as soon as possible in animals and humans to reach compelling conclusions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9034594     DOI: 10.1007/bf00046345

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  67 in total

1.  Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Authors:  S A Rosenberg; M T Lotze; J C Yang; P M Aebersold; W M Linehan; C A Seipp; D E White
Journal:  Ann Surg       Date:  1989-10       Impact factor: 12.969

2.  Finally, a successful adjuvant therapy for high-risk melanoma.

Authors:  C M Balch; A C Buzaid
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

3.  Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report.

Authors:  J Bubeník; P Perlmann; M Indrová; J Símová; T Jandlová; J Neuwirt
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

Review 4.  Somatic gene therapy of human melanoma: preclinical studies and early clinical trials.

Authors:  G Parmiani; M P Colombo
Journal:  Melanoma Res       Date:  1995-10       Impact factor: 3.599

Review 5.  Cytokine-induced tumor immunogenicity: from exogenous cytokines to gene therapy.

Authors:  G Forni; M Giovarelli; F Cavallo; M Consalvo; A Allione; A Modesti; P Musiani; M P Colombo
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-11

Review 6.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

7.  An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4.

Authors:  F Pericle; M Giovarelli; M P Colombo; G Ferrari; P Musiani; A Modesti; F Cavallo; F Di Pierro; F Novelli; G Forni
Journal:  J Immunol       Date:  1994-12-15       Impact factor: 5.422

8.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

Authors:  A Belldegrun; L M Muul; S A Rosenberg
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

9.  Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness.

Authors:  H Kawamura; S A Rosenberg; J A Berzofsky
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

10.  Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.

Authors:  P Paglia; C Chiodoni; M Rodolfo; M P Colombo
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  2 in total

1.  Paracrine effects of IL-4 transfection on TS/A adenocarcinoma cells mediate reduced in vivo growth.

Authors:  S Pacor; R Gagliardi; P Spessotto; G Zabucchi; G Sava
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

2.  Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent systemic immunity only against B7-expressing tumours.

Authors:  H Chong; G Hutchinson; I R Hart; R G Vile
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.